Bulletin
Investor Alert

London Markets Open in:

Oct. 18, 2019, 7:28 a.m. EDT

Antibody Drug Conjugate Market Size to Hit $ 10.1 Bn by 2026

Oct 18, 2019 (Market Prediction via COMTEX) -- According to ARC’s latest market research report, The global Antibody Drug Conjugate Market worth $10.1 billion by 2026 and growing CAGR around 26.3 % during the forecast period from 2018 to 2026.

The Global Antibody Drug Conjugate Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2026.

Key Players & Strategies

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Antibody Drug Conjugate Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues.

Some vital players in the Antibody Drug Conjugate Market include AbbVie Inc.; Seattle Genetics, Inc. .; F. Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited and Pfizer Inc.

New product innovations, partnerships and contracts are the producers’ main policies. Companies have tried to create fresh products and techniques to create low-cost Antibody Drug Conjugate Market and industrial amounts. As pricing is one of the main limiting factors, companies have increasingly invested in developing fresh techniques to decrease manufacturing expenses. Moreover, many manufacturers work with other businesses to create fresh applications for their products.

Request a Sample Copy of this Research Report at https://www.acumenresearchandconsulting.com/request-sample/1046

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in this market research report.

Scope of the Antibody Drug Conjugate Market Report:

The study provides a decisive view of the Antibody Drug Conjugate Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Key Takeaways:

  • What is the market size in 2018 and the growth rate of this research report?

  • What is the market drivers, restrains, opportunities governing the global Antibody Drug Conjugate Market?

  • Which is the largest and the fastest growing segments in this report?

  • Who are the key players operating in the market and their market position?

  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

Market Segmentation as below:

Market By Application

  • Blood Cancer

  • Breast Cancer

  • Ovarian Cancer

  • Lung Cancer

  • Brain Tumor

Market By End-user

  • Hospitals

  • Clinics

  • ASC

  • Homecare

  • Others

Market By Technology

  • Cleavable Linker

  • Non-cleavable Linker

Market By Geography

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East and Africa (MEA)

Regional Insights

In 2017, North America was the biggest revenue producing region, trailed by Europe. The main consideration ascribing for their proceeded with strength incorporates the nearness of critical market players, for example, Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most settled market as far as the use of ADCs combined with entrenched medicinal services foundation, and patient mindfulness.

North America is anticipated to observe the quickest development over the estimate time frame as a large portion of the ADCs at present in pipeline are being produced in U.S. Additionally, the U.S. Nourishment and Drug Administration (FDA) is one of the principal administrative bodies to endorse ADC in U.S. Subsequently, these components are probably going to help showcase development in the area over the estimate time frame.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Antibody Drug Conjugate
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antibody Drug Conjugate Market By Application
1.2.2.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.2.2. Global Antibody Drug Conjugate Market Revenue Share By Application in 2017
1.2.2.3. Blood Cancer
1.2.2.4. Breast Cancer
1.2.2.5. Ovarian Cancer
1.2.2.6. Lung Cancer
1.2.2.7. Brain Tumor
1.2.2.8. Others
1.2.3. Antibody Drug Conjugate Market By End-user
1.2.3.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By End-user (2015-2026)
1.2.3.2. Hospitals
1.2.3.3. Clinics
1.2.3.4. ASC
1.2.3.5. Homecare
1.2.3.6. Others
1.2.4. Antibody Drug Conjugate Market By Technology
1.2.4.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.4.2. Cleavable Linker
1.2.4.3. Non-cleavable Linker
1.2.4.4. Others
1.2.5. Antibody Drug Conjugate Market by Geography
1.2.5.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibody Drug Conjugate Major Manufacturers in 2017

CHAPTER 4. ANTIBODY DRUG CONJUGATE MARKET BY APPLICATION

4.1. Global Antibody Drug Conjugate Revenue By Application
4.2. Blood Cancer
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Breast Cancer
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Ovarian Cancer
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Lung Cancer
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Brain Tumor
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.7. Other
4.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. ANTIBODY DRUG CONJUGATE MARKET BY END-USER

5.1. Global Antibody Drug Conjugate Revenue By End-user
5.2. Hospitals
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Clinics
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. ASC
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Homecare
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. ANTIBODY DRUG CONJUGATE MARKET BY TECHNOLOGY

6.1. Global Antibody Drug Conjugate Revenue By Technology
6.2. Cleavable Linker
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Non-cleavable Linker
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

7.1. North America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antibody Drug Conjugate Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
7.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

8.1. Europe Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

9.1. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

10.1. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

11.1. Middle East Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 12. AFRICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

12.1. Africa Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Africa Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. AbbVie Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Seattle Genetics, Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Takeda Pharmaceutical Company Limited
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Pfizer Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1046

The report is readily available and can be dispatched immediately after payment confirmation.

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

COMTEX_354851354/2637/2019-10-18T07:27:47

Link to MarketWatch's Slice.